Healthcare >> CEO Interviews >> April 6, 2009
LEN BRANDT co-founded CNS Response, Inc., in 2000 and is its CEO. In many ways,
this has resulted from his venture capital investment experience, which taught
him of the significant need for technology advancement in mental and addictive
medicine and his operational experience in building a company from the ground
up. His prior experience is extensive in new ventures from both venture capital
and operating perspectives. As a General Partner at Norwest Ventures he led the
fund's investment activity throughout the 1980s in all areas of health care
including biopharmaceutical, healthcare services, medical devices and
diagnostics. Most of these investments were in early stages of development where
Mr. Brandt had a lead role. In the 1990s, he co-founded Mill City Venture
Consulting, Inc., providing venture consulting to a diverse number of ventures
ranging from medical device to financial services. During this time he co-
founded Embro Vascular, the dominant supplier of technology for least-invasive
saphenous vein harvesting (heart bypass surgery) now supplied through Boston
Scientific. Also during this time, his involvement with an innovative supplier
of neurostimulation lead technology, Micronet Medical, (purchased by Advanced
Neuromodulation Systems and then St. Jude Medical, refocused his attention on
CNS analytics and treatment. From 1995 to 1999 he headed Time Segment
Publishing, a company he founded. Mr. Brandt was educated at the University of
Illinois and Harvard. After moving to Orange County, California, he has
continued to be active with new ventures and entrepreneurs in advisory or Board
directory roles and co-founded myGenopedia. Profile
TWST: Would you please begin with a brief introduction and history of CNS Response?
Mr. Brandt: CNS Response became a company through the efforts of Steve Suffin
and his colleagues, after